Companies: 10,795·Total market cap: $144.5T
Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals, Inc.

CPRXNASDAQHealthcare● Active
$31.27
$-0.02(-0.06%)
Market Cap$3.8B
P/E Ratio
52W High$32.56
52W Low$19.05
Overview

Catalyst Pharmaceuticals, Inc. (CPRX) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · CPRX · as of Jun 8, 2026

Key Statistics

EPS (TTM)$1.80cprx eps ttm · cprx earnings per shareEarnings history
PE Ratio (TTM)17.4×cprx pe ratio ttm · cprx price to earningsPE Ratio deep dive
Revenue (TTM)$597.0Mcprx revenue ttm · cprx annual revenueFull revenue history
Dividend YieldNo Dividenddoes cprx pay dividends · cprx dividend yieldDividend history
Shares Outstanding122.3Mcprx shares outstanding · cprx floatShares outstanding history
Next EarningsAug 5, 2026Est.cprx earnings date · cprx next earningsEarnings history

Financial Snapshot

Full Financials
FY 2025Revenue$589.0M▲ +19.78% YoY
202320242025
catalyst pharmaceuticals, inc. revenue · cprx revenue 2025
FY 2025Net Income$214.3M▲ +30.78% YoY
202320242025
catalyst pharmaceuticals, inc. net income · cprx profit 2025
FY 2025EPS$1.75▲ +26.81% YoY
202320242025
cprx eps · catalyst pharmaceuticals, inc. earnings per share 2025
TTM:Revenue: $597.0MNet Income: $221.3MEPS: $1.80View income statement →

Analyst Ratings & Price Target

Full Forecast
SellBuy
Buy16 analystsis cprx a buy · cprx analyst rating
Strong Buy
0
Buy
12
Hold
4
Sell
0
Strong Sell
0
12-Month Price Target
$31.50Low
$31.27Current
$31.75Avg Target1.54% upside
$32.00High
cprx price target · cprx 12 month forecast

Total: 16 · Buy rate: 75.0%

The CPRX analyst consensus is Buy, based on ratings from 16 Wall Street analysts over the past 3 months. The average 12-month price target is $31.75, representing +1.54% upside from the current price of $31.27.

Stock Performance

Full History
1D-0.06%
1W+0.00%
1M+0.39%
3M+29.00%
YTD+33.98%
1Y+21.01%
5Y+456.41%

About Catalyst Pharmaceuticals, Inc.

CEORichard John Daly
IPO DateNov 8, 2006
Employees181
CountryUS

Catalyst Pharmaceuticals, Inc. a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurolog…

what is catalyst pharmaceuticals, inc. · cprx stock overview · catalyst pharmaceuticals, inc. company profile · who is catalyst pharmaceuticals, inc. ceo · cprx NASDAQ · catalyst pharmaceuticals, inc. headquarters · catalyst pharmaceuticals, inc. business segments

About Stock Overview & Key Data

Catalyst Pharmaceuticals, Inc. (CPRX) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Nov 8, 2006. As of the latest trading session, CPRX stock price is $31.27, with a market capitalization of $3.8B. The stock has returned +21.01% over the past 12 months and +33.98% year-to-date.

According to 16 Wall Street analysts, the consensus rating for Catalyst Pharmaceuticals, Inc. stock is Buy, with an average 12-month price target of $31.75. In fiscal year 2025, Catalyst Pharmaceuticals, Inc. reported revenue of $589.0M and net income of $214.3M. For detailed data — including Catalyst Pharmaceuticals, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.

Frequently Asked Questions

As of the latest trading session, Catalyst Pharmaceuticals, Inc. (CPRX) stock price is $31.27. The stock is traded on NASDAQ under the ticker symbol CPRX. The 52-week range is $19.05 – $32.56.

CPRX stock priceCPRX quote todaylive ticker
Data provided by Financial Modeling PrepLast updated: Jun 8, 2026Not investment advice